Linear Growth and Final Height Characteristics in Adolescent Females with Anorexia Nervosa

Dalit Modan-Moses1,3*, Amit Yaroslavsky2*, Brigitte Kochavi2, Anat Toledano2, Sharon Segev2, Fadel Balawi2, Edith Mitran2, Daniel Stein2,3

1 Pediatric Endocrinology and Diabetes Unit, The Edmond and Lily Safra Children’s Hospital, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel, 2 Pediatric Psychosomatic Department, The Edmond and Lily Safra Children’s Hospital, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel, 3 The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Objective: Growth retardation is an established complication of anorexia nervosa (AN). However, findings concerning final height of AN patients are inconsistent. The aim of this study was to assess these phenomena in female adolescent inpatients with AN.

Methods: We retrospectively studied all 211 female adolescent AN patients hospitalized in an inpatient eating disorders department from 1/1/1987 to 31/12/99. Height and weight were assessed at admission and thereafter routinely during hospitalization and follow-up. Final height was measured in 69 patients 2–10 years after discharge. Pre-morbid height data was available in 29 patients.

Results: Patients’ height standard deviation scores (SDS) on admission (−0.285 ± 1.0) and discharge (−0.271 ± 1.02) were significantly (p < 0.001) lower than expected in normal adolescents. Patients admitted at age ≤ 13 years, or less than 1 year after menarche, were more severely growth-impaired than patients admitted at an older age, (p = 0.03). Final height SDS, available for 69 patients, was −0.258 ± 1.04, significantly lower than expected in a normal population (p = 0.04), and was more severely compromised in patients who were admitted less than 1 year from their menarche. In a subgroup of 29 patients with complete growth data (pre-morbid, admission, discharge, and final adult height), the pre-morbid height SDS was not significantly different from the expected (−0.11 ± 1.1), whereas heights at the other time points were significantly (p = 0.001) lower (−0.56 ± 1.2, −0.52 ± 1.2, and −0.6 ± 1.2, respectively).

Conclusions: Our findings suggest that whereas the premorbid height of female adolescent AN patients is normal, linear growth retardation is a prominent feature of their illness. Weight restoration is associated with catch-up growth, but complete catch-up is often not achieved.

Introduction

Malnutrition or systemic diseases often result in growth deceleration and stunting. While nutritional rehabilitation or disease remittance results in accelerated linear growth, [1–3], catch-up growth is often incomplete, resulting in compromised final adult height [1,4,5]. Despite the well-described association between nutrition and growth, only few systemized studies assessed the effect of undernutrition during puberty on growth rate and final adult height. Moreover, while catch-up growth is easily recognized in the pre-pubertal period, it is often difficult to discriminate between the accelerated growth rate of the normal pubertal spurt and the occurrence of catch-up growth in nutritionally rehabilitated malnourished pubertal adolescents.

Anorexia nervosa (AN), which affects about 1% of adolescent females, is characterized by an intense fear of gaining weight, self-imposed semi-starvation, weight loss, and amenorrhea [6]. The disease provides an attractive model for studying the effect of caloric restriction during adolescence on growth and final height, since in AN patients undernutrition occurs in the absence of other physical illness, and weight rehabilitation is planned and controlled.

Several studies reported growth failure or short stature in patients with AN [7–14] (Table 1) or other forms of voluntary caloric restriction [15–17]. Possible contributors to growth retardation in these patients include hypothyroxinemia, hypercortisolism, hypogonadism [18–20], and growth hormone resistance [21–25]. However, despite the relatively high prevalence of AN in adolescent females [24–25], data regarding final height of AN patients are scarce and inconclusive [2,10,13]. Reports describing catch-up growth in AN range from failure to gain any height [7] to complete catch-up growth [2,7,12,15] (Table 1). This apparent
Patients and Methods

Patients

All female AN patients (n = 211), hospitalized in the Pediatric Psychosomatic Department of the Edmond and Lily Safra Children’s Hospital from 1/1/1987 to 31/12/1999 were included in this study, and their medical charts were retrospectively reviewed.

The study was approved by the hospital’s review board. AN diagnosis as summarized in the medical records was re-assessed independently by two experienced psychiatrists (D.S., A.Y.) according to the criteria of the DSM-IV, using the Eating Disorders Family History Interview (EDFHI) [26] that has been validated in Israeli samples [27].

The patients did not receive any psychotropic medications prior to admission or during the first month of inpatient treatment. Therefore, antidepressant agents were administered during hospitalization in about 50% of the patients upon achieving a body mass index (BMI) of at least 17 kg/m². While these medications may increase appetite, cause weight gain, and alter endocrine function, to the best of our knowledge, they do not significantly influence linear growth [28].

Management

After assessment of the nutritional status, a nutritional rehabilitation program geared toward weight-gain of 0.5–1.0 kg/week was constructed. Target weight was established according to age and the estimated potential height. Patients were discharged upon reaching their target weight and maintaining it for at least two weeks.

After discharge, patients were followed biweekly during the first two months, monthly for the next four months, and thereafter, every three months until reaching the age of 18. Target weight was readjusted every three months during follow-up in patients who had not finished growing, and was increased gradually to allow for the expected height gain, based on the potential height.

Height and Weight Measurements

Standing height was measured to the nearest 0.1 cm, using a wall mounted stadiometer. All measurements were taken during the morning hours by a single investigator (A.T.), using standardized procedures [29]. Body weight was obtained to the nearest 0.1 kg, with the patient wearing a hospital gown and without any footwear.

Pre-morbid height and weight measurements, when available, were obtained from the primary care physician and/or the school nurse.

Final height (defined conservatively as height at age 18 or older, and at least 3 years after menarche) was measured in our center in 69 patients 2–10 years following discharge from their index hospitalization. Height SDSs were calculated based on the 2000 sex-specific growth charts from the CDC (www.cdc.gov/growthcharts). These data have been found adequate for assessing Israeli children [30].

| ref | n     | Height | Premorbid | Dg/admission | Follow-up | Final       |
|-----|-------|--------|-----------|--------------|-----------|-------------|
| 2   | F = 58, M = 13 | na     | na        |              | 1 = catch-up, 2 = na | “As expected” |
| 7   | F = 1, M = 2   | nl     | decreased | 11 patients had catch-up |             |
| 8   | F = 13, M = 2  | na     | decreased | Na          | na        |
| 9   | M = 10         | na     | decreased | Na          | na        |
| 10  | F = 16         | na     | decreased | Ht-SDS improved | Near FH < TH |
| 11  | M = 11         | nl     | decreased | Ht-SDS improved | FH < pre-morbid height SDS and TH- SDS |
| 12  | F = 46         | nl     | decreased | Ht-SDS normalized | na        |
| 13  | F = 681*, Ctl = 832 | na     | na     | Na          | Decreased** |
| 14  | F = 63, Ctl 79  | na     | nl      | nl growth (1 year) | na        |
| 31  | F = 58, M = 8   | F = nl, M = tall | F = decreased, M = na | F = decreased, M = na | na        |

Abbreviations: F = female; M = male; Ctl = control; na = not available; pats = patients; FH = final height; TH = midparental target height.

*The mean age of onset in participants with AN was 17.9±3.4 years.
**Onset before the age of 16, the analysis showed there was a significant effect of both age of onset and lowest BMI.

doi:10.1371/journal.pone.0045504.t001
Data Analysis

Height SDSs at the various time points were compared to the expected in the normal population using the one-sample t-test. Height and weight on admission and discharge were compared using the paired t-test. ANOVA with repeated measures was used for comparing changes in height SDSs over time in patients who had multiple measurements, and in subgroups of patients (younger vs. older). Results were considered significant if the two-sided p-value was <0.05. Calculations were performed using SPSS 14.0, a statistical software package.

Results

Baseline Characteristics of the Study Patient (n = 211)

The mean age of the patients on admission was 16.6 ± 4.2 years; their mean BMI was 15.7 ± 1.02 kg/m², and their mean age at menarche was 12.7 ± 2.4 years.

Weight Gain during Hospitalization (n = 211)

Patients’ weight increased significantly (p < 0.001) during hospitalization (5.3 ± 8.2 months). Average weight gain was 7.98 ± 6.43 kg.

Linear Growth during Hospitalization and Weight Rehabilitation (n = 211)

Mean height SDS on admission was −0.285 ± 1.02, significantly lower than expected in a normal population (p < 0.001). During hospitalization, height SDS increased to −0.271 ± 1.02, but was still significantly lower than expected in a normal population (p < 0.001).

ANOVA with repeated measures revealed that the extent of growth impairment was more severe among patients admitted at an age of 13 years or younger, compared to patients admitted at an older age, on both admission and discharge (p = 0.03). Similarly, ANOVA with repeated measures revealed that patients admitted less than 1 year after menarche had more severe growth-impairment on admission than patients admitted more than 1 year after menarche (height SDS −0.38 ± 1.01 vs. −0.19 ± 0.92, p = 0.03) (figure 1). There was a trend toward greater improvement in height SDS during hospitalization among patients admitted less than 1 year after menarche (figure 1), but this did not reach significance.

Final Height Data (n = 69)

Final height was available for 69 patients (32.7%). Three of the original cohort of 211 candidates had died (2%; data obtained from the death records of the Israel Ministry of Interior Affairs). Comparison of patients who were evaluated for final height to those who were not, showed no differences for year of birth, ethnic origin, age at the onset of AN and at hospitalization, time from the onset of AN to hospitalization in our department, duration of hospitalization, minimal body mass index (BMI), subtype of AN at onset of AN to hospitalization, duration of hospitalization, and number of hospitalizations, and duration of AN prior to hospitalization had no significant affect on final height SDS.

On admission, the mean height SDS of these 69 patients was −0.231 ± 1.103, significantly lower than expected in a normal population (p < 0.001). During hospitalization, height SDS increased to −0.197 ± 1.122, but was still significantly lower than expected in a normal population (p < 0.001). Mean final height SDS was −0.258 ± 1.04 (161.6 ± 6.8 cm), which, similar to the admission and discharge height SDS, was significantly lower than expected in a normal population (p = 0.04).

Factors Affecting Catch-up Growth and Final Height

Height SDS on admission was a strong predictor of final height SDS (p < 0.001). BMI-SDS upon admission was negatively correlated with the change in height-SDS between admission and final height (r = −0.306, p = 0.011). Other factors, including weight gain during hospitalization, duration of hospitalization, and number of hospitalizations, and duration of AN prior to hospitalization had no significant affect on final height SDS.

To test our hypothesis that patients admitted at earlier stages of puberty will have a greater potential for catch-up growth compared to patients hospitalized at later pubertal stages, we divided the 69 patients for whom final height was available into those who were admitted less than 1 year after menarche and patients admitted more than 1 year from menarche. A significant (p = 0.019) interaction was found between final height and pubertal status at admission. Hence, in contrast to our hypothesis, patients who were admitted less than 1 year after menarche showed less catch-up growth and their final height was more severely compromised in comparison to patients admitted more than one year after menarche (figure 2).

Comparison of Admission, Discharge, and Final Height with Pre-morbid Growth Characteristics (n = 29)

Complete growth data (i.e., pre-morbid, admission, discharge, and final height) was available for 29 patients. The mean pre-morbid height SDS of this sub-group was −0.11 ± 1.1, similar to that expected in a normal population. At the time of admission, the mean height SDS was lower, −0.56 ± 1.2, indicating a decrease in linear growth prior to admission. During hospitalization, height SDS increased marginally to −0.32 ± 1.2 but remained lower than the pre-morbid height SDS. The mean final height SDS was −0.6 ± 1.2 (159.3 ± 7 cm), again lower than the pre-morbid height SDS (figure 3).

ANOVA with repeated measures revealed a significant (p = 0.001) time effect. Using contrasts to compare the various time points revealed that the pre-morbid height-SDS was significantly different from the other three time points, which were all similar. It could be argued that some of our patients achieved final height prior to admission, and therefore had little potential for catch-up growth. We therefore repeated the analysis excluding 14 patients who were likely at or near final height at the time of admission (age > 16 years, more than 2 years after menarche).

The results for the remaining 15 patients (age < 16 years and less then 2 years after menarche) were similar: pre-morbid height SDS in this SUB-group (−0.11 ± 1.010) was significantly higher compared to height SDS at admission (−0.67 ± 1.33), at discharge (−0.71 ± 1.3), and at final height −0.81 ± 1.21 (Figure 3).

Discussion

The aim of the present study was to assess linear growth retardation characteristics in adolescent females with AN, with particular attention to the period post weight restoration. Based on our findings in male patients [11] we hypothesized that female AN patients would show significant growth retardation upon hospitalization, and that weight restoration would be associated with a significant, although not complete, catch up growth. Our results support this hypothesis, as growth impairment was indeed prevalent in our group of adolescent female AN inpatients, admission until attainment of final adult height.

The mean height SDS on admission for all 211 patients was −0.285 ± 1.02, significantly lower than expected in a normal population. In the subgroup of patients with complete growth
data, the mean pre-morbid height SDS was not significantly different from the expected in a normal population, whereas mean height SDS on admission was significantly lower. These results are in agreement with Swenne et. al and Nielsen [12,31] (Table 1), and suggest that the decreased height SDS observed on admission reflects actual growth retardation, rather than an increased predilection to AN in females with short stature as suggested elsewhere [13]. Furthermore, our findings imply that early signs of AN may not be detected in a significant number of patients, and that the diagnosis of the disorder is often delayed.

Patients admitted at age 13 years or younger, and patients admitted less than one year after menarche presented with more severe growth-impairment compared to patients admitted at an older age. A possible explanation of this finding is that some of the older patients may have already accomplished most of their linear growth prior to the onset of AN.

Weight restoration resulted in accelerated linear growth and improvement in height SDS during hospitalization. Still, complete catch-up growth was not achieved, and the mean final height SDS of our patients was significantly lower than expected in a normal population, and not significantly different from height SDS on admission. Considering the pre-morbid records, our data suggest that compromised final adult height was the result of prolonged malnutrition and not related to pre-morbid short stature. This notion is further supported by the finding that BMI-SDS upon admission was negatively correlated with the difference between height-SDS on admission and at final height, implying that patients with a greater degree of malnutrition upon admission had a lesser degree of catch-up growth.

Several hormonal changes may contribute to growth retardation in AN. These include low thyroxine and triiodothyronine, elevated cortisol, and low sex hormone levels. Growth hormone (GH) resistance - characterized by GH hypersecretion, and low

Figure 1. The correlation of pubertal status at admission with height SDS on admission and discharge from hospitalization.
doi:10.1371/journal.pone.0045504.g001
serum levels of growth hormone binding protein, insulin-like growth factor I (IGF-I), and insulin-like growth factor binding-protein 3 (IGF-BP3) - has also been related to growth failure in AN patients. These changes are reversible with weight gain, with a gradual increase in thyroid hormone levels, gonadotropins and IGF-I, and a decrease in GH and cortisol levels (19, 32). In addition, it has been suggested that leptin may act as a skeletal growth factor and induce longitudinal growth (33). Since leptin levels are low in underweight AN patients and increase with re-feeding (32), it is possible that hypoleptinemia may contribute to growth retardation in AN, whereas the increase in leptin levels with weight restoration may contribute to catch-up.

Several smaller studies [7–9,11,12] (Table 1) described the occurrence of growth retardation in AN. However, whether growth retardation seen at the time of diagnosis of AN affects final adult height has not yet been established. Two studies suggested that adolescents with AN can realize their height potential. Pfeiffer et al [2] assessed final adult height in 13 males and 58 female AN patients, claiming that most patients reached their expected heights. However, final height percentile was compared with height percentile at diagnosis, with no reference to pre-morbid height. Thus, height deceleration prior to admission could have been missed. Moreover, since only limited information was given regarding the patients’ age distribution, it is possible that at least some of them reached final height prior to the onset of AN.

Prabhakaran et al [14] followed 63 female AN adolescents for one year. They found that height at study entry, as well as the difference between target height and both follow-up height and predicted adult height did not differ between patients and controls, suggesting the preservation of height potential in female AN adolescents. However, no information was given regarding the premorbid height of the AN patients, and final height was not assessed. Furthermore, this study included patients treated as outpatients that might have had a milder disease course compared

Figure 2. The correlation of pubertal status on admission with final adult height.
doi:10.1371/journal.pone.0045504.g002
to the inpatients included in our study. In keeping with this assumption, the investigators reported that girls with longer duration of illness had lower height SDSs and lower predicted height SDSs [14].

By contrast, the results of Lantzouni et al [10] in 16 females with early onset AN, and of Lanes and Soros [17] in healthy children after prolonged period of inadequate caloric intake, were similar to ours. Both groups reported decreased height SDS at presentation. Despite accelerated growth following nutritional rehabilitation, the patients did not achieve their predicted final height [17] or their target height [10,17].

As emphasized earlier, the occurrence of growth impairment in our patients well before hospitalization suggests a considerable delay in the diagnosis of AN. We hypothesize that weight loss in our patients may have been masked by their reduced height: once growth retardation occurs, the severity of malnutrition may be underestimated because weight is related to the “stunted” height rather than to the pre-morbid projected height, resulting in a weight-per-height/BMI SDS that may seem reasonable. In addition, growth impairment may have not been recognized in adolescents whose heights were in the upper percentiles. This is illustrated in figure 4 - the patient depicted in this figure shifted from the 90th to the 50th height percentile well before AN has been noticed, perhaps because she still appeared normal relative to her peers (Fig. 4). Irrespective of the reason, a delay in the diagnosis of AN in adolescent, and perhaps even more so in pre-adolescent females, may result in severe malnutrition and compromised final height. Furthermore, since AN may be associated with irreversible multi-organ damage including brain atrophy [34,35], osteoporosis [36], and major adverse obstetric outcomes [37], we postulate that stunting of growth may be viewed as a measurable marker of covert tissue injury. Thus, we believe that early diagnosis of AN and early aggressive nutritional rehabilitation are of utmost importance in order to prevent not only growth failure but also irreversible tissue damage with long-term implications.

![Figure 3. Changes in height SDS in 29 anorexia nervosa patients with complete growth data.](http://example.com/figure3.png)

It has been suggested that the hypogonadism found in AN may lead to delay in growth-plate closure [14], allowing, in turn, for compensatory growth with the potential for catch-up during later adolescence. Hence, we hypothesized that patients admitted at a younger age, with seemingly significant growth potential, will show the greatest degree of catch-up growth. However, in contrast to our hypothesis, and similar to the findings of Favaro et al [13], these patients actually had the worst outcome regarding final height. Thus, it seems that prolonged undernutrition, arising (albeit not diagnosed) during early adolescence and continuing around the critical time of peak height velocity, may interfere with growth and result in irreversible stunting despite the delay in skeletal maturity.

Our series is one of the largest series describing growth in female AN patients. It provides important pre-morbid, follow-up and final-height data not previously available in other series. Nevertheless, several limitations should be considered. Our study included only inpatient AN female adolescents, so that our findings cannot be generalized to less severe forms of the disorder. Secondly, we did not include matched controls. Thirdly, only a third of the original cohort had final height data, and premorbid height was reported in only a minority, although no difference was shown between patients with and without final height data in any of the demographic and clinical parameters evaluated. Although we made an attempt to contact all former patients, many refused to come for a final assessment, or have not been located. This was likely the result of our department being a tertiary care center that hospitalizes patients from all over Israel, reducing the likelihood of continuation of treatment in our center following discharge. Finally, Tanner stages of sexual development, bone age studies, parental heights, and results of laboratory tests were not recorded in most of the charts. Therefore, we were unable to calculate the pre-morbid predicted adult height and the mid-parental target height, or to investigate the relationships between pubertal stages and adult height.
catch-up growth. These patients present an unusual growth pattern that cannot be explained based on genetic height potential or timing of puberty.

Despite these limitations, our study provides strong evidence to support our hypothesis. In particular, the strength of our study relies on the data obtained from the subgroup of patients with pre-morbid and final height measurements (figure 3), showing normal pre-morbid height followed by growth deceleration and almost no catch-up growth. These patients present an unusual growth pattern that cannot be explained based on genetic height potential or timing of puberty.

References

1. Prader A, Tanner JM, von Harnack GA (1963) Catch-up growth following illness or starvation. An example of developmental canalization in man. J of Ped 62: 646–659.
2. Pfeiffer RJ, Lucas AR, Istrup DM (1986) Effect of anorexia nervosa on linear growth. Clin Ped 25: 7–12.
3. Kirschner DS, Klüch JR, Kalman SS, deFavaro MV, Rosenberg IH (1981) Reversal of growth retardation in Crohn’s disease with therapy emphasizing oral nutritional restitution. Gastroenterology 80: 10–5.
4. Acheson RM (1960) Effects of nutrition and disease on human growth. Symp Soc Humana Biol 3: 73.
5. Gafni RI, Baron J (2000) Catch-up growth: possible mechanisms. Pediatr Nephrol 14: 616–9.
6. American Psychiatric Association (1994) Diagnostic and Statistical Manual for the Diagnosis of Mental Disorders, 4th edition, American Psychiatric Press.
7. Root AW, Powers PS (1983) Anorexia nervosa presenting as growth retardation in adolescents. J Adolesc Health Care 4: 25–30.
8. Danziger Y, Makamel M, Zeharia A, Dinari G, Mimouni M (1994) Stunting of male adolescents with anorexia nervosa. J Adolesc Health 16: 448–53.
9. Siegel JH, Hartoff D, Golden NH, Shenker IR (1995) Medical complications in male adolescents with anorexia nervosa. J Adolesc Health 16: 448–53.
10. Lantzouni E, Frank GR, Golden NH, Shenker RI (2002) Reversibility of growth stunting in early onset anorexia nervosa: a prospective study. J Adolesc Health 31: 162–5.
11. Modan-Moses D, Yaroslavsky A, Novikov I, Segev S, Toledoano A, et al. (2003) Stunting of growth as a major feature of anorexia nervosa in male adolescents. Pediatrics 111: 270–6.
12. Swerene I (2005) Weight requirements for catch-up growth in girls with eating disorders and onset of weight loss before menarche. Int J Eat Disord 38: 340.
13. Favaro A, Tenconi E, Degorges D, Soave M, Zanetti T, et al. (2007) Association between low height and eating disorders: cause or effect? Int J Eat Disord 40: 549–53.
14. Prabhakaran R, Mira M, Miller KK, Kruczek K, Sundaralingam S, et al. (2008) Determinants of height in adolescent girls with anorexia nervosa. Pediatrics 121: e1317–23.
15. Pagliara MT, Lelahz F, Grad G, Fort P, Marks-Katz M (1983) Fear of obesity. A cause of short stature and delayed puberty. N Engl J Med 309: 513–8.
16. Davis DR, Apley J, Fill G, Grimaldi C (1978) Diet and retarded growth. Br Med J [Clin Res] 1: 539–42.
17. Lanes R, Soros A (2004) Decreased final height of children with growth deceleration secondary to poor weight gain during late childhood. J Pediatr 145: 1281–30.
18. Mackenzie R, Neinstein LS (1996) Anorexia nervosa and bulimia. In: Neinstein LS, editor. Adolescent health care - a practical guide, 3rd ed. Philadelphia: Williams and Wilkins; 564–581.
19. Miller KK (2011) Endocrine dysregulation in anorexia nervosa update. J Clin Endocrinol Metab 96: 2939–49.
20. Warren MP (1995) Anorexia nervosa and other eating disorders. In: Becker KL, editor. Principles and practice of endocrinology and metabolism, 2nd ed. Philadelphia: J.B. Lippincott Co. 1169–1173.
21. Golden NH, Kreitzer P, Jacobson MS, Chasalow FI, Schebendach J, et al. (1994) Disturbances in growth hormone secretion and action in adolescents with anorexia nervosa. J Pediatr 125: 655–60.
22. Stoving RK, Flyvbjerg A, Frystyk J, Fisker S, Hangaard J, et al. (1999) Low density of women who have recovered from anorexia nervosa. J Am Acad Child Adolesc Psychiatry 38: 209–17.
23. Stein D, Mayyan R, Ram A, Loewenthal R, Achiron A, et al. (2005) Circulatory neurosteroid levels in underweight female adolescent anorexia nervosa inpatients and following weight restoration. Eur Neuropsychopharmacol 15: 647–53.
24. Klein DF, Rowland LP (1996) Current psychotropic drugs, Brunner Mazel, New York.
25. Tanner J (1994) Azoxyology. In: Kappy MS, Blizzard RM, Migeon CJ, editors. The diagnosis and treatment of endocrine disorders in childhood and adolescence, 4th ed. Springfield: Charles C Thomas, Publisher; 154–158.
26. Stein D, Acheson R, Kriek EE, Sack J (2001) Comparison of body weight and height of Israeli schoolchildren with the Tanner and Centers for Disease Control and Prevention growth charts. Pediatrics 108: E108.
27. Nielsen S (1983) Evaluation of growth in anorexia nervosa from serial measurements. J Pediatr 103: 227–30.
28. Modan-Mosel D, Stein D, Patience C, Yaroslavsky A, Ram A, et al. (2007) Modulation of adiponectin and leptin during refeeding of female anorexia nervosa patients. J Clin Endocrinol Metab 92: 1843–7.
29. Atkinson R, Atkinson E, Sally B, Kolodny S, Neutel C, et al. (2004) Leptin reverses the inhibitory effect of caloric restriction on longitudinal growth. Endocrinology 145: 343–50.
30. Kerem NC, Katzman DK (2003) Brain structure and function in adolescents with anorexia nervosa. Adolesc Med 14: 109–18.
31. Chai HT, Christensen BK, Zepusk NY, Richards BA, Hantratt MK, et al. (2008) Cognitive function and brain structure in females with a history of adolescent-onset anorexia nervosa. Pediatrics 122: e126–37.
32. Hartman D, Greg A, Brown R, Rackow C, Atkinson R, et al. (2000) Bone density of women who have recovered from anorexia nervosa. Int J Eat Disord 28: 107.
33. Micali N, Simonsoff E, Treasure J (2007) Risk of major adverse perinatal outcomes in women with eating disorders. Br J Psychiatry 190: 255.
34. Tanner JM, Davis PS (1981) Clinical longitudinal standards for height and weight velocity for North American children. J Pediatr 107: 317–29.
35. Hartman D, Grig A, Brown R, Rackow C, Atkinson R, et al. (2000) Bone density of women who have recovered from anorexia nervosa. Int J Eat Disord 28: 107.
36. Stein D, Acheson R, Kriek EE, Sack J (2001) Comparison of body weight and height of Israeli schoolchildren with the Tanner and Centers for Disease Control and Prevention growth charts. Pediatrics 108: E108.
37. Modan-Mosel D, Stein D, Patience C, Yaroslavsky A, Ram A, et al. (2007) Modulation of adiponectin and leptin during refeeding of female anorexia nervosa patients. J Clin Endocrinol Metab 92: 1843–7.
38. Stein D, Mayyan R, Ram A, Loewenthal R, Achiron A, et al. (2005) Circulatory neurosteroid levels in underweight female adolescent anorexia nervosa inpatients and following weight restoration. Eur Neuropsychopharmacol 15: 647–53.
39. Klein DF, Rowland LP (1996) Current psychotropic drugs, Brunner Mazel, New York.
40. Tanner J (1994) Azoxyology. In: Kappy MS, Blizzard RM, Migeon CJ, editors. The diagnosis and treatment of endocrine disorders in childhood and adolescence, 4th ed. Springfield: Charles C Thomas, Publisher; 154–158.
41. Golden TK, Hacyon U, Kroll E, Sack J (2001) Comparison of body weight and height of Israeli schoolchildren with the Tanner and Centers for Disease Control and Prevention growth charts. Pediatrics 108: E108.
42. Moen M, Neumann E, Corell C, Ernould C, Albert A, et al. (1999) Leptin reverses the inhibitory effect of caloric restriction on longitudinal growth. Endocrinology 145: 343–50.
43. Kerem NC, Katzman DK (2003) Brain structure and function in adolescents with anorexia nervosa. Adolesc Med 14: 109–18.
44. Chai HT, Christensen BK, Zepusk NY, Richards BA, Hantratt MK, et al. (2008) Cognitive function and brain structure in females with a history of adolescent-onset anorexia nervosa. Pediatrics 122: e126–37.
45. Hartman D, Grig A, Brown R, Rackow C, Atkinson R, et al. (2000) Bone density of women who have recovered from anorexia nervosa. Int J Eat Disord 28: 107.
46. Micali N, Simonsoff E, Treasure J (2007) Risk of major adverse perinatal outcomes in women with eating disorders. Br J Psychiatry 190: 255.
47. Tanner JM, Davies RS (1981) Clinical longitudinal standards for height and weight velocity for North American children. J Pediatr 107: 317–29.
48. Albanese A, Stanhope R (1995) Predictive factors in the determination of final adult height and final adult height in males with constitutional delay of growth and puberty. J Pediatr 122: 545–50.
49. LaFranchi S, Hauna CE, Mandel SH (1991) Constitutional delay of growth: expected versus final adult height. Pediatrics 87: 82–7.
50. Crowne EC, Shalet SM, Wallace WH, Emsmon DM, Price DA (1991) Final adult height of children with untreated constitutional delay in growth and puberty. J Pediatr 119: 501–04.
51. LaFranchi S, Hauna CE, Mandel SH (1991) Constitutional delay of growth: expected versus final adult height. Pediatrics 87: 82–7.
52. Crowne EC, Shalet SM, Wallace WH, Emsmon DM, Price DA (1991) Final adult height of children with untreated constitutional delay in growth and puberty. J Pediatr 119: 501–04.
53. LaFranchi S, Hauna CE, Mandel SH (1991) Constitutional delay of growth: expected versus final adult height. Pediatrics 87: 82–7.
54. Crowne EC, Shalet SM, Wallace WH, Emsmon DM, Price DA (1991) Final adult height of children with untreated constitutional delay in growth and puberty. J Pediatr 119: 501–04.
55. LaFranchi S, Hauna CE, Mandel SH (1991) Constitutional delay of growth: expected versus final adult height. Pediatrics 87: 82–7.
56. Crowne EC, Shalet SM, Wallace WH, Emsmon DM, Price DA (1991) Final adult height of children with untreated constitutional delay in growth and puberty. J Pediatr 119: 501–04.